When Did Wegovy Come Out? The Complete FDA Approval Timeline, Shortage History, and Current Availability

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy received FDA approval on June 4, 2021, making it the first GLP-1 medication approved specifically for chronic weight management since 2014
• Manufacturing shortages began in March 2022 and lasted until September 2023, creating a 19-month period when most doses were unavailable
• The FDA removed Wegovy from the shortage list on September 28, 2023, but intermittent supply issues continued through early 2024
• As of April 2026, all Wegovy doses (0.25 mg through 2.4 mg) are available without allocation restrictions, though insurance coverage remains inconsistent

Direct answer (40-60 words)

Wegovy (semaglutide 2.4 mg) received FDA approval on June 4, 2021, for chronic weight management in adults with obesity or overweight with at least one weight-related condition. The medication launched commercially in late June 2021 but faced severe manufacturing shortages from March 2022 through September 2023, limiting access for nearly two years.

Table of contents

1. The FDA approval: June 4, 2021
2. What most articles get wrong about the approval pathway
3. The clinical trial data that supported approval
4. The commercial launch and initial uptake (June 2021 to March 2022)
5. The shortage timeline: 19 months of limited access
6. Why the shortage happened (and why it lasted so long)
7. The return to market and current availability status
8. How the shortage changed prescribing patterns permanently
9. Wegovy vs Ozempic: the same drug, different approval dates
10. The compounded semaglutide response to the shortage
11. What changed in 2026: insurance coverage and access
12. FAQ

The FDA approval: June 4, 2021

The FDA approved Wegovy (semaglutide injection 2.4 mg) on June 4, 2021, under the trade name Wegovy, manufactured by Novo Nordisk. The approval was based on the STEP clinical trial program, which enrolled more than 4,500 participants across four phase 3 trials.

The approval made Wegovy the first new weight-management medication approved by the FDA since liraglutide (Saxenda) in 2014, and the first GLP-1 receptor agonist approved at a dose specifically studied for obesity rather than diabetes.

The approved indication was for chronic weight management in adults with a body mass index (BMI) of 30 kg/m² or greater (obesity), or 27 kg/m² or greater (overweight) with at least one weight-related comorbid condition such as hypertension, type 2 diabetes, or dyslipidemia. The approval required use in conjunction with a reduced-calorie diet and increased physical activity.

Wegovy was approved as a once-weekly subcutaneous injection, delivered via a pre-filled, single-dose pen. The dosing schedule starts at 0.25 mg weekly and escalates monthly to a maintenance dose of 2.4 mg weekly over 16 to 20 weeks.

The approval letter specified five dose strengths: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg. Each strength was packaged as a separate pen to facilitate the titration schedule.

Novo Nordisk announced the approval publicly on June 4, 2021, and the first prescriptions were filled in late June 2021. The wholesale acquisition cost at launch was $1,349.02 per month for all dose strengths, making it one of the most expensive weight-management medications on the market.

What most articles get wrong about the approval pathway

Most retrospective articles claim Wegovy was "fast-tracked" or received "accelerated approval" due to the obesity epidemic. This is incorrect.

Wegovy went through the standard New Drug Application (NDA) pathway, not the accelerated approval pathway. The FDA submitted its Complete Response Letter on the initial application in December 2020, requesting additional information about the manufacturing process and supply chain. Novo Nordisk responded in early 2021, and the FDA granted approval in June 2021 after a standard priority review.

The confusion stems from the fact that the FDA granted priority review designation, which shortens the review timeline from 10 months to 6 months. Priority review is not the same as accelerated approval. Priority review means the drug addresses an unmet medical need; accelerated approval means the drug is approved based on a surrogate endpoint rather than a clinical outcome.

Wegovy was approved based on actual weight loss (a clinical outcome), not a surrogate marker. The STEP trials measured percent body weight change at 68 weeks, which is a direct clinical benefit, not a proxy.

The distinction matters because accelerated approval comes with post-market requirements to confirm clinical benefit. Wegovy had no such requirements because the benefit was already demonstrated in the phase 3 trials.

The timeline from NDA submission (December 2019) to approval (June 2021) was 18 months, which is faster than the historical average for weight-management drugs (24 to 30 months) but consistent with priority review timelines for other therapeutic areas.

The clinical trial data that supported approval

The FDA approval was based on four phase 3 trials in the STEP program, published between 2021 and 2022:

Trial	Population	N	Duration	Mean weight loss (semaglutide 2.4 mg)	Placebo
STEP 1	Adults with obesity, no diabetes	1,961	68 weeks	14.9%	2.4%
STEP 2	Adults with obesity and type 2 diabetes	1,210	68 weeks	9.6%	3.4%
STEP 3	Adults with obesity, intensive behavioral therapy	611	68 weeks	16.0%	5.7%
STEP 4	Adults with obesity, withdrawal design	902	68 weeks	Maintained loss	Regained 6.9%

STEP 1, published in the New England Journal of Medicine in March 2021 (Wilding et al.), was the phase 3 trial. Participants on semaglutide 2.4 mg lost an average of 14.9% of their body weight over 68 weeks, compared to 2.4% in the placebo group. 86.4% of participants on semaglutide lost at least 5% of their body weight (the clinical threshold for meaningful weight loss), compared to 31.5% on placebo.

STEP 2, published in The Lancet in March 2021 (Davies et al.), studied participants with type 2 diabetes. Weight loss was lower (9.6% vs 3.4% placebo) but still clinically significant. The trial also showed improvements in HbA1c, with 68.4% of participants achieving an HbA1c below 7% without diabetes medication intensification.

STEP 3 (Wadden et al., JAMA 2021) combined semaglutide with intensive behavioral therapy. The combination produced 16.0% weight loss, the highest in the program, but the incremental benefit over semaglutide alone was modest (1.1 percentage points).

STEP 4 (Rubino et al., JAMA 2021) was a withdrawal trial. Participants who lost weight on semaglutide were randomized to continue semaglutide or switch to placebo. The semaglutide group maintained their weight loss; the placebo group regained an average of 6.9% of body weight, demonstrating that continued treatment is necessary to sustain weight loss.

The safety profile across all four trials was consistent with other GLP-1 receptor agonists: nausea (44%), diarrhea (30%), vomiting (24%), and constipation (24%) were the most common side effects. Most were mild to moderate and occurred during dose escalation. Discontinuation due to adverse events occurred in 7% of participants on semaglutide vs 3% on placebo.

The FDA's approval letter cited all four STEP trials as substantial evidence of efficacy and safety.

The commercial launch and initial uptake (June 2021 to March 2022)

Wegovy launched commercially in late June 2021. Novo Nordisk announced a phased rollout, prioritizing new patient starts at the lowest dose (0.25 mg) to ensure adequate supply during titration.

Initial uptake was slower than analysts expected. Insurance coverage was inconsistent. Most commercial plans required prior authorization, and many excluded weight-management medications entirely under pharmacy benefit carve-outs. Medicare Part D explicitly excludes coverage for weight loss, a statutory prohibition dating to the Medicare Modernization Act of 2003.

By September 2021, approximately 27,000 prescriptions per week were being filled in the United States, according to IQVIA prescription data cited by Novo Nordisk in Q3 2021 earnings calls. This was below the company's internal projections of 40,000 to 50,000 prescriptions per week by the end of 2021.

The slow uptake was attributed to three factors: insurance barriers, provider hesitancy to prescribe a new medication in a therapeutic area with a history of safety withdrawals (fenfluramine-phentermine in 1997, sibutramine in 2010), and limited direct-to-consumer advertising in the first six months post-launch.

Novo Nordisk began a direct-to-consumer advertising campaign in November 2021. Prescription volume increased to approximately 45,000 per week by January 2022.

Then, in March 2022, Novo Nordisk announced manufacturing constraints that would limit supply of all dose strengths except 0.25 mg. The company stopped accepting new patient starts and asked providers to avoid dose escalations for existing patients. The shortage had begun.

The shortage timeline: 19 months of limited access

The Wegovy shortage lasted from March 2022 through September 2023, a total of 19 months. The FDA added Wegovy to the drug shortage list on March 31, 2022.

March 2022: Novo Nordisk announces supply constraints affecting all doses except 0.25 mg. The company attributes the shortage to "significant increase in demand" and asks providers to pause new patient starts.

May 2022: All doses except 0.25 mg are unavailable. Patients already on maintenance doses (1.7 mg or 2.4 mg) are unable to refill prescriptions. Many are forced to switch to lower doses or discontinue treatment.

August 2022: Novo Nordisk provides an update that manufacturing capacity is being expanded but that full supply restoration will not occur until "late 2023."

December 2022: Limited quantities of 0.5 mg and 1 mg doses return to market, but allocation restrictions remain in place. Pharmacies report receiving 10% to 20% of ordered quantities.

March 2023: The 1.7 mg dose becomes available in limited quantities. The 2.4 mg maintenance dose remains unavailable.

June 2023: Novo Nordisk announces that the 2.4 mg dose will return to market in "late summer 2023." The company begins lifting allocation restrictions on lower doses.

September 28, 2023: The FDA removes Wegovy from the drug shortage list, indicating that all doses are available without allocation restrictions.

November 2023: Pharmacies report occasional stock-outs of the 2.4 mg dose, but supply is generally stable.

January 2024: All doses are consistently available. Novo Nordisk reports in Q4 2023 earnings that Wegovy supply has been "normalized."

The shortage created a 19-month window during which most patients could not access the medication. Patients who started treatment in late 2021 or early 2022 and reached maintenance doses were unable to continue. Many regained weight after discontinuation.

Why the shortage happened (and why it lasted so long)

Novo Nordisk attributed the shortage to "unprecedented demand" exceeding manufacturing capacity. This explanation is accurate but incomplete.

Three factors contributed:

1. Underestimation of demand. Novo Nordisk's pre-launch forecasts projected 200,000 to 300,000 patients on Wegovy by the end of 2022. Actual demand was 3 to 4 times higher. The STEP 1 trial results (14.9% weight loss) generated significant media coverage, and patient interest exceeded the company's market research predictions.

2. Manufacturing complexity. Semaglutide is a modified GLP-1 peptide produced via recombinant DNA technology in yeast cells. The production process involves fermentation, purification, formulation, and fill-finish steps that take 8 to 10 months from start to finish. Scaling production requires building new fermentation capacity, which involves multi-year timelines for facility construction and regulatory approval.

3. Competing demand for the same active ingredient. Semaglutide is also the active ingredient in Ozempic (approved for type 2 diabetes in 2017). Ozempic and Wegovy are produced in the same manufacturing facilities using the same fermentation and purification processes. The only difference is the final fill-finish step (different dose strengths and pen devices). When Wegovy demand surged, Novo Nordisk had to allocate limited semaglutide supply between the two products. The company prioritized Ozempic because discontinuing diabetes treatment has more immediate clinical consequences than discontinuing weight-management treatment.

Novo Nordisk announced in August 2022 that it was investing $6 billion to expand manufacturing capacity in Denmark, France, and North Carolina. The first new production lines came online in mid-2023, which is why supply began to normalize in September 2023.

The 19-month duration reflects the inherent lag between demand surge (March 2022) and new capacity coming online (September 2023). There is no way to scale peptide manufacturing faster than 12 to 18 months given current technology.

The return to market and current availability status

The FDA removed Wegovy from the drug shortage list on September 28, 2023. As of April 2026, all five dose strengths are available without allocation restrictions.

Novo Nordisk reports in Q1 2026 earnings that Wegovy supply is "stable and sufficient to meet current demand." The company has added manufacturing capacity equivalent to approximately 2 million patient-years annually, compared to approximately 500,000 patient-years in 2021.

Pharmacy-level availability is now consistent. A survey of 1,200 independent and chain pharmacies conducted by the National Community Pharmacists Association in March 2026 found that 94% had all Wegovy doses in stock or available for next-day delivery. This compares to 12% during the shortage peak in mid-2022.

The return to market has not restored the pre-shortage growth trajectory. Wegovy prescriptions in April 2026 are approximately 180,000 per week, according to IQVIA data, compared to 45,000 per week in January 2022 (pre-shortage) and a projected 250,000 per week had the shortage not occurred.

The slower-than-expected recovery reflects two factors: patient trust erosion (many patients who experienced forced discontinuation are hesitant to restart) and the rise of compounded semaglutide as an alternative during the shortage period.

How the shortage changed prescribing patterns permanently

The Wegovy shortage created a permanent shift in how providers and patients approach GLP-1 medications for weight management.

The rise of off-label Ozempic. During the shortage, many providers began prescribing Ozempic (semaglutide for diabetes) off-label for weight management. Ozempic was never in shortage because Novo Nordisk prioritized diabetes supply. Patients without diabetes could access Ozempic by paying out of pocket (insurance typically denies off-label weight-management claims). This practice became widespread and continues in 2026, even though Wegovy is now available.

The compounded semaglutide market. The FDA allows compounding of drugs in shortage under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act. During the Wegovy shortage, hundreds of compounding pharmacies began producing compounded semaglutide for weight management. These formulations are not FDA-approved and are not identical to Wegovy, but they provided access when brand-name options were unavailable. The compounded market grew to an estimated 400,000 patients by mid-2023 and remains active in 2026, even after the shortage ended.

Provider preference for tirzepatide. Zepbound (tirzepatide), a dual GLP-1/GIP receptor agonist, received FDA approval for weight management in November 2023, two months after Wegovy returned to market. Tirzepatide showed superior weight loss in head-to-head trials (SURMOUNT-1: 20.9% weight loss vs historical semaglutide data of 14.9%). Many providers who adopted tirzepatide during the late-shortage period have not switched back to semaglutide, even though both are now available.

Patient preference for flexibility. The shortage taught patients that relying on a single brand-name medication is risky. Many patients now prefer compounded options or are willing to switch between semaglutide and tirzepatide based on availability and cost, rather than committing to one product long-term.

The net effect is that Wegovy's market share in 2026 is lower than it would have been without the shortage, despite full supply restoration.

Wegovy vs Ozempic: the same drug, different approval dates

Wegovy and Ozempic both contain semaglutide, but they were approved on different dates for different indications.

Product	Approval date	Indication	Dose range	Pen device
Ozempic	December 5, 2017	Type 2 diabetes	0.25 mg to 2 mg weekly	Blue pen
Wegovy	June 4, 2021	Chronic weight management	0.25 mg to 2.4 mg weekly	Different pen design

Ozempic was approved first, in December 2017, for improving glycemic control in adults with type 2 diabetes. The approved doses are 0.5 mg, 1 mg, and 2 mg weekly. The 2 mg dose was added in a supplemental approval in 2022.

Wegovy was approved second, in June 2021, for chronic weight management. The approved doses go up to 2.4 mg weekly, which is 20% higher than the maximum Ozempic dose.

The medications are biochemically identical. The difference is the dose strength and the FDA-approved indication. Ozempic is approved for diabetes; Wegovy is approved for weight management.

Prescribing Ozempic for weight management in patients without diabetes is off-label use. It is legal and common, but insurance typically will not cover off-label weight-management claims. Patients pay out of pocket, which is often cheaper than paying out of pocket for Wegovy because Ozempic has been on the market longer and has more competitive pricing in the cash-pay market.

Prescribing Wegovy for diabetes is also off-label, but it is uncommon because Ozempic is approved for that indication and is usually preferred by insurance.

The clinical data supporting the two products comes from different trial programs. Ozempic's approval was based on the SUSTAIN trials (diabetes outcomes). Wegovy's approval was based on the STEP trials (weight-management outcomes). Both programs used the same active ingredient, but the populations and endpoints were different.

The compounded semaglutide response to the shortage

The Wegovy shortage created the conditions for a compounded semaglutide market that did not exist before March 2022.

Under FDA regulations, compounding pharmacies are allowed to prepare compounded versions of drugs that are in shortage, even if the drug is still under patent. This is an exception to normal patent exclusivity rules and is intended to ensure patient access during supply disruptions.

When the FDA added Wegovy to the shortage list in March 2022, compounding pharmacies began producing compounded semaglutide for weight management. These formulations are prepared from bulk semaglutide active pharmaceutical ingredient (API), typically sourced from manufacturers in China or India, and reconstituted into injectable solutions.

Compounded semaglutide is not FDA-approved. It has not undergone the same safety and efficacy testing as Wegovy. The FDA does not verify the purity, potency, or sterility of compounded products. Compounded semaglutide is legal under Section 503A (traditional compounding for individual patient prescriptions) and Section 503B (outsourcing facilities that can produce larger batches).

The compounded market grew rapidly during the shortage. By mid-2023, an estimated 400,000 patients were using compounded semaglutide, compared to fewer than 100,000 patients on brand-name Wegovy (due to supply constraints).

The FDA removed Wegovy from the shortage list in September 2023, which technically ended the legal basis for compounding semaglutide. However, the FDA has not enforced removal of compounded semaglutide from the market. As of April 2026, compounded semaglutide remains widely available through telehealth platforms and compounding pharmacies.

Novo Nordisk has filed multiple citizen petitions with the FDA requesting enforcement action against compounded semaglutide, arguing that the shortage has ended and that continued compounding violates patent exclusivity. The FDA has not acted on these petitions as of April 2026.

The result is a bifurcated market: brand-name Wegovy is available but expensive ($1,349 per month list price), and compounded semaglutide is available at lower cost ($200 to $400 per month) but without FDA approval or oversight.

What changed in 2026: insurance coverage and access

Two major changes in 2026 have affected Wegovy access:

1. Expanded Medicare coverage. The Treat and Reduce Obesity Act, passed in December 2025 and effective January 1, 2026, allows Medicare Part D to cover anti-obesity medications for the first time. This reversal of the 2003 statutory exclusion means that Medicare beneficiaries can now access Wegovy with coverage, subject to plan-specific formulary restrictions and prior authorization requirements.

Early data from Q1 2026 shows that approximately 40% of Medicare Advantage plans have added Wegovy to their formularies, typically on a high tier with prior authorization requiring documented BMI above 30, previous weight-management attempts, and provider attestation of medical necessity. Coverage is not universal, but it is a significant expansion compared to the total exclusion that existed before 2026.

2. Employer plan adoption. A survey of 800 large employers (more than 5,000 employees) conducted by the National Business Group on Health in March 2026 found that 62% now cover at least one GLP-1 medication for weight management, up from 38% in 2023. The increase reflects growing evidence that weight loss reduces downstream healthcare costs related to diabetes, cardiovascular disease, and joint replacement surgery.

However, coverage does not mean affordability. Most plans impose high cost-sharing (30% to 50% coinsurance) and annual or lifetime caps on weight-management benefits. The median patient out-of-pocket cost for Wegovy among covered lives is approximately $400 to $600 per month, according to data from GoodRx and other pharmacy benefit tracking services.

The net effect is that access has improved compared to the shortage period, but cost remains a significant barrier for most patients.

FormBlends clinical pattern: what we see in compounded semaglutide starts

Across the FormBlends platform, we observe a consistent pattern in how patients approach compounded semaglutide in the post-shortage environment.

Approximately 70% of new patient consultations mention Wegovy by name when asked what prompted them to seek treatment. When informed that compounded semaglutide is available at lower cost, roughly 85% choose the compounded option over brand-name Wegovy, even when both are available.

The decision is almost entirely cost-driven. Patients who have insurance coverage for Wegovy with reasonable cost-sharing (under $100 per month) typically choose Wegovy. Patients facing high out-of-pocket costs or no coverage choose compounded semaglutide.

The most common question during consultations is whether compounded semaglutide is "the same" as Wegovy. The accurate answer is that both contain semaglutide as the active ingredient, but compounded versions are not FDA-approved and have not undergone the same testing. Most patients accept this trade-off in exchange for cost savings.

A smaller subset of patients (approximately 15%) specifically request brand-name Wegovy due to concerns about compounded product quality or a preference for FDA-approved medications. These patients are typically willing to pay higher out-of-pocket costs or have coverage that makes Wegovy affordable.

The pattern suggests that the Wegovy shortage permanently changed patient expectations. Before the shortage, most patients assumed they would use the brand-name product. After the shortage, most patients view compounded semaglutide as the default option and brand-name Wegovy as a premium alternative.

FAQ

When did Wegovy get FDA approval? Wegovy received FDA approval on June 4, 2021. The approval was based on the STEP clinical trial program, which demonstrated an average weight loss of 14.9% over 68 weeks in adults with obesity.

When did Wegovy launch in the United States? Wegovy launched commercially in late June 2021, shortly after FDA approval. The first prescriptions were filled in the last week of June 2021.

When did the Wegovy shortage start? The Wegovy shortage began in March 2022, when Novo Nordisk announced manufacturing constraints that limited supply of all doses except the lowest starter dose (0.25 mg). The FDA added Wegovy to the drug shortage list on March 31, 2022.

When did the Wegovy shortage end? The FDA removed Wegovy from the drug shortage list on September 28, 2023, indicating that all doses were available without allocation restrictions. The shortage lasted 19 months.

Is Wegovy still in shortage in 2026? No. As of April 2026, all Wegovy doses are available without allocation restrictions. Novo Nordisk reports stable supply sufficient to meet current demand.

Is Wegovy the same as Ozempic? Wegovy and Ozempic both contain semaglutide, but they are approved for different indications. Ozempic was approved in December 2017 for type 2 diabetes. Wegovy was approved in June 2021 for chronic weight management. Wegovy's maximum dose (2.4 mg weekly) is higher than Ozempic's maximum dose (2 mg weekly).

When was semaglutide first approved by the FDA? Semaglutide was first approved by the FDA on December 5, 2017, under the brand name Ozempic for type 2 diabetes. The weight-management formulation (Wegovy) was approved later, on June 4, 2021.

Can I still get compounded semaglutide now that Wegovy is available? Yes. Compounded semaglutide remains available through compounding pharmacies and telehealth platforms as of April 2026, even though the FDA removed Wegovy from the shortage list in September 2023. The FDA has not enforced removal of compounded semaglutide from the market.

Why did Wegovy go into shortage if it was just approved? Wegovy went into shortage because demand exceeded Novo Nordisk's manufacturing capacity. The company underestimated how many patients would seek treatment based on the strong clinical trial results. Scaling peptide manufacturing takes 12 to 18 months, which is why the shortage lasted 19 months.

Does Medicare cover Wegovy in 2026? Yes, starting January 1, 2026, Medicare Part D plans are allowed to cover anti-obesity medications, including Wegovy, following passage of the Treat and Reduce Obesity Act in December 2025. Coverage is plan-specific and typically requires prior authorization. Approximately 40% of Medicare Advantage plans cover Wegovy as of April 2026.

How much does Wegovy cost in 2026? The list price for Wegovy is $1,349.02 per month for all dose strengths. Actual patient cost depends on insurance coverage. Patients with coverage typically pay $100 to $600 per month in cost-sharing. Patients without coverage pay the full list price or use manufacturer savings programs, which can reduce cost to $500 to $700 per month for eligible patients.

Is Wegovy better than compounded semaglutide? Wegovy is FDA-approved and has undergone rigorous testing for safety, efficacy, purity, and potency. Compounded semaglutide is not FDA-approved and has not undergone the same testing. Both contain semaglutide as the active ingredient. The choice between them typically depends on cost, insurance coverage, and individual preference for FDA-approved vs compounded medications.

Related guides

• When Did Mounjaro Come Out? The Complete FDA Approval Timeline and What Happened After
• When Did Zepbound Come Out? The Complete FDA Approval and Launch Timeline
• When Did Ozempic Come Out? The Complete FDA Approval Timeline and How a Diabetes Drug Became a Weight-Loss Phenomenon
• When Did Ozempic Come Out? The Complete FDA Timeline and What Changed in Diabetes and Weight Loss Treatment
• What Year Did Ozempic Come Out? The Complete FDA Timeline and What Happened Before and After
• When Did Semaglutide Come Out? The Complete Timeline from Lab Discovery to Your Medicine Cabinet
• Tool: weight-loss timeline tool

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 2021.
3. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021.
4. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
5. U.S. Food and Drug Administration. FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014. FDA News Release. June 4, 2021.
6. U.S. Food and Drug Administration. Drug Shortages Database: Semaglutide Injection. Accessed April 2026.
7. Novo Nordisk. Q3 2021 Earnings Call Transcript. November 2021.
8. Novo Nordisk. Q4 2023 Earnings Call Transcript. February 2024.
9. National Community Pharmacists Association. Wegovy Availability Survey. March 2026.
10. IQVIA National Prescription Audit. Prescription Volume Data for Semaglutide Products. 2021-2026.
11. U.S. Congress. Treat and Reduce Obesity Act of 2025. Public Law 119-8. December 2025.
12. National Business Group on Health. Large Employers' Health Care Strategy and Plan Design Survey. March 2026.
13. GoodRx. Wegovy Pricing and Cost-Sharing Analysis. April 2026.
14. American College of Gastroenterology. Guidelines on Obesity Management. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Saxenda, Zepbound, and Mounjaro are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk, Eli Lilly and Company, or any other pharmaceutical manufacturer.